Hormone Therapy Prescribing Patterns in the United States
- 1 November 2004
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 104 (5, Part 1), 1042-1050
- https://doi.org/10.1097/01.aog.0000143826.38439.af
Abstract
OBJECTIVE: We sought to examine prescribing patterns (prevalence and rates of initiation and discontinuation) for estrogen plus progestin (hormone therapy [HT] and estrogen alone [ET]) in the United States in the 2 years before the published results of Women's Health Initiative's (WHI) HT trial's early termination and for 5 months after their release. METHODS: We conducted an observational cohort study of 169,586 women aged 40–80 years who were enrolled in 5 health maintenance organizations in the United States to estimate the prevalence of HT and ET and discontinuation and initiation rates between September 1, 1999, to June 31, 2002 (baseline), and December 31, 2002 (follow-up). We used automated pharmacy data to identify all oral and transdermal estrogen and progestin dispensed during the study period. RESULTS: The prevalence of HT declined 46% from baseline to follow-up (14.6% to 7.9%); ET use declined 28% during the same period (12.6% to 9.1%). The discontinuation of HT increased almost immediately, from 2.5% at baseline to 13.8% in October 2002. We saw an immediate decrease in HT and ET initiation rates, from 0.4% and 0.3% at baseline, respectively, to 0.2% for HT and ET at follow-up. CONCLUSION: The diffusion of the WHI HT trial results had an immediate impact on the discontinuation of HT and ET and is likely responsible for the 46% and 28% decline in the initiation of these respective therapies. Further exploration of why women continue to use HT and identification of methods for addressing reasons for continued use are indicated. LEVEL OF EVIDENCE: II-2Keywords
This publication has 29 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Use of Hormone Replacement Therapy by Postmenopausal Women in the United StatesAnnals of Internal Medicine, 1999
- Design of the Women’s Health Initiative Clinical Trial and Observational StudyControlled Clinical Trials, 1998
- Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United StatesCancer Causes & Control, 1997
- Postmenopausal Hormone Use and Risk of Large-Bowel CancerJNCI Journal of the National Cancer Institute, 1995
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a reviewMaturitas, 1990
- Decreased Risk of Fractures of the Hip and Lower Forearm with Postmenopausal Use of EstrogenThe New England Journal of Medicine, 1980